Current concepts in research related to oncogenes implicated in salivary gland tumourigenesis: A review of the literature

Oral Diseases

Volumn 15, Issue 4, 2009, Pages 249-254

  Elledge, R ^a,b  

^a ROYAL SHREWSBURY HOSPITAL   (United Kingdom)

^b PRINCESS ROYAL HOSPITAL   (United Kingdom)

Author keywords

Cancer; Oncogenes; Salivary gland

Indexed keywords

AXITINIB; CETUXIMAB; ERLOTINIB; GEFITINIB; HIGH MOBILITY GROUP A2 PROTEIN; IMATINIB; PROTEIN MDM2; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR SOX4; TRASTUZUMAB;

ADENOID CYSTIC CARCINOMA; CARCINOGENESIS; CLINICAL TRIAL; DNA SEQUENCE; DRUG MECHANISM; GENE FUNCTION; GENE MUTATION; HMG1 C GENE; HUMAN; LUNG CANCER; MAML2 GENE; ONCOGENE; ONCOGENE C FOS; ONCOGENE H RAS; ONCOGENE NEU; ONCOGENE RAS; PLAG1 GENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SALIVARY GLAND CARCINOMA; SALIVARY GLAND TUMOR; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; ONCOGENES; PROGNOSIS; SALIVARY GLAND NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 64549152529     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2009.01529.x     Document Type: Review

References (78)

1. Agulnik M, Cohen EW, Cohen RB et al (2007). Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and nonadenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 25 : 3978 3984.
2. Alcedo JC, Fabrega JM, Arosemena JR, Urrutia A (2004). Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: report of two successfully treated cases. Head Neck 26 : 829 831.
3. Anderson DM, Lyman SD, Baird A et al (1990). Molecular cloning of mast cell growth factor, a haematopoietin that is active in both membrane bound and soluble forms. Cell 63 : 235 243.
4. Augello C, Gregorio V, Bazan V et al (2006). TP53 and p16INK4A, but not H-KI-Ras, are involved in tumorigenesis and progression of pleomorphic adenomas. J Cell Physiol 207 : 654 659.
5. Birek C, Lui E, Dardick I (1993). c-fos oncogene underexpression in salivary gland tumours as measured by in situ hybridisation. Am J Pathol 142 : 917 923.
6. Bourne HR, Sanders DA, McCormick F (1990). The GTPase superfamily: a conserved switch for diverse cell functions. Nature 348 : 125 132.
7. Brandwein-Gensler M, Hille J, Wang BY et al (2004). Low grade salivary duct carcinoma: description of 16 cases. Am J Surg Pathol 28 : 1040 1044.
8. Chidzonga MM, Lopez VM, Portilla-Alvarez AL (1995). Salivary gland tumours in Zimbabwe: a report of 282 cases. Int J Oral Maxillofac Surg 24 : 293 297.
9. Croce CM (2008). Oncogenes and cancer. N Engl J Med 358 : 502 511.
10. Dagrada GP, Negri T, Tamborini E, Pierotti MA, Pilotti S (2004). Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in situ hybridization and immunohistochemistry. Histopathology 44 : 301 302.
11. Deguchi H, Hamano H, Hayashi Y (1993). c-myc, ras p21 and p53 expression in pleomorphic adenoma and its malignant form of the human salivary glands. Acta Pathol Jpn 43 : 213 222.
12. DiPalma S, Skalova A, Vanieek T, Simpson RH, Starek I, Leivo I (2005). Non-invasive (intracapsular) carcinoma ex pleomorphic adenoma: recognition of focal carcinoma by HER-2/neu and MIB1 immunohistochemisty. Histopathology 46 : 144 152.
13. Ehrhardt A, Ehrhardt GRA, Guo X, Schrader JW (2002). Ras and relatives job-sharing and networking keep an old family together. Exp Haematol 30 : 1089 1106.
14. El-Naggar AK, Lovell M, Killary AM, Clayman GL, Batsakis JG (1996). A mucoepideroid carcinoma or minor salivary gland with t(11;19)(q21;p13.1) as the only karyotypic abnormality. Cancer Genet Cytogenet 87 : 29 33.
15. Eveson JW, Cawson RA (1985a). Salivary gland tumours: a review of 2410 cases with particular reference to histological types, site, age and sex distribution. J Pathol 146 : 51 58.
16. Eveson JW, Cawson RA (1985b). Tumours of minor (oropharyngeal) salivary glands: a demographic study of 336 cases. J Oral Pathol 14 : 500 509.
17. Faivre S, Raymond E, Casiraghi O, Temam S, Berthaud P (2005). Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J Clin Oncol 23 : 6271 6273.
18. Fong T, Morgensztern D, Govindan R (2008). EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer. J Thorac Oncol. 3 : 303 310.
19. Frierson HF Jr., El-Naggar AK, Welsh JB et al (2002). Large scale molecular analysis identifies genes with altered expression in salivary adenoid cystic carcinoma. Am J Pathol 161 : 1315 1323.
20. Geurts JM, Schoenmakers EF, Roijer E et al (1997). Expression of reciprocal hybrid transcripts of HMGIC and FHIT in a pleomorphic adenoma of the parotid gland. Cancer Res 57 : 13 17.
21. Geurts JM, Schoenmakers EF, Roijer E et al (1998). Identification of NFIB as a recurrent translocation partner gene of HMGIC in pleomorphic adenomas. Oncogene 16 : 865 872.
22. Glisson BS, Blumenschein G, Francisco M et al (2005). Phase II trial of gefitinib in patients with incurable salivary gland cancer. J Clin Oncol 23 : 5532.
23. Hancock JF (2003). Ras proteins: different signals from different locations. Nat Rev Mol Cell Biol 4 : 273 284.
24. Horsman DE, Berean K, Durham JS (1995). Translocation (11;19)(q21;p13.1) in mucoepidermoid carcinoma of the salivary gland. Cancer Genet Cytogenet 80 : 165 166.
25. Hotte SJ, Winquist EW, Lamont E et al (2005). Imatinib mesylate in patients with adenoid cystic cancers or the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol 23 : 585 590.
26. Huang E, Nocka K, Beier DR et al (1990). The haematopoietic growth factor KL is encoded by the S1 locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 63 : 225 233.
27. Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Loning T (2005). Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer 103 : 2526 2533.
28. Jeng YM, Lin CY, Hsu HC (2000). Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett 154 : 107 111.
29. Johnson CJ, Barry MB, Vasef MA, Deyoung BR (2008). Her2/neu expression in salivary duct carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Appl Immunohistochem Mol Morphol 16 : 54 58.
30. Komiya T, Park Y, Modi S et al (2006). Sustained expression of Mect1-Maml2 is essential for tumour cell growth in salivary gland cancers carrying the t(11;19) translocation. Oncogene 25 : 6128 6132.
31. Kousvelari E, Yeh CK, Mertz PM, Chinchetru M (1990). Regulation of proto-oncogenes and salivary gland cell proliferation. Adv Dent Res 4 : 61 68.
32. Lai EC (2004). Notch signalling: control of cell communication and cell fate. Development 131 : 965 973.
33. Lassam N, Bickford S (1992). Loss of c-kit expression in cultured melanoma cells. Oncogene 7 : 51 56.
34. Locati LD, Bossi P, Perrone F et al (2008). Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol : Doi :.
35. Martin FH, Suggs SV, Langley KE et al (1990). Primary structure and functional expression of rat and human stem cell factor DNAs. Cell 63 : 203 211.
36. Martins C, Cavaco B, Tonon G, Kaye FJ, Soares J, Fonseca I (2004). A study of MECT1-MAML2 in mucoepidermoid carcinoma and Warthin's tumour of salivary glands. J Mol Diagn 6 : 205 210.
37. McCracken S, Kim CS, Xu Y et al (1997). An alternative pathway for expression of p56lck from type I promoter transcripts in colon carcinoma. Oncogene 15 : 2929 2937.
38. Milasin J, Pujic N, Dedovic N et al (1993). H-ras gene mutations in salivary gland pleomorphic adenomas. Int J Oral Maxillofac Surg 22 : 359 361.
39. Moon RT, Bowerman B, Boutros M, Perrimon N (2002). The promise and perils of Wnt signalling through beta-catenin. Science 296 : 1644 1646.
40. Nabili V, Tan JW, Bhuta S, Sercarz JA, Head CS (2007). Salivary duct carcinomas: a clinical and histologic review with implications for transtuzumab therapy. Head Neck 29 : 907 912.
41. Nguyen LH, Black MJ, Hier M, Chauvin P, Rochon L (2003). HER2/neu and Ki-67 as prognostic indicators in mucoepidermoid carcinoma of the salivary glands. J Otorlaryngol 32 : 328 331.
42. Nocka K, Buck J, Levi E, Besmer P (1990). Candidate ligand for the c-kit tyrosine kinase receptor: KL, a fibroblast derived growth factor stimulates mast cells and erythroid progenitors. EMBO J 9 : 3287 3294.
43. Oda K, Matsuoka Y, Funahashi A, Kitano H (2005). A comprehensive pathway map of epidermal growth factor signalling. Mol Syst Biol 1 : 2005 2010.
44. Okabe M, Miyabe S, Nagatsuka H et al (2006). MECT1-MAML2 fusion transcript defines a favourable subset of mucoepidermoid carcinoma. Clin Cancer Res 12 : 3902 3907.
45. Orton RJ, Sturm OE, Vyshermisky V, Calder M, Gilbert DR, Kolch W (2005). Computational modelling of the receptor-tyrosine-kinase-activated MAPK pathway. Biochem J 392 : 249 261.
46. Ostman J, Anneroth G, Gustafsson H et al (1997). Malignant salivary gland tumours in Sweden 1960-1989 - an epidemiological study. Oral Oncol 33 : 169 176.
47. Penner CR, Folpe AL, Budnick SD (2002). C-kit expression distinguishes salivary gland adenoid cystic carcinoma from polymorphous low grade adenocarcinoma. Mod Pathol 15 : 687 691.
48. Persson F, Andren Y, Winnes M et al (2009). High resolution genomic profiling of adenomas and carcinomas of the salivary glands reveals amplification, rearrangement and fusion of HMGA2. Genes Chromosomes Cancer 48 : 69 82.
49. Pfeffer MR, Talmi Y, Catane R, Symon Z, Yosepovitch A, Levitt M (2007). A phase II study of imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol 43 : 33 36.
50. Piechocki MP, Yoo GH, Dibbley SK, Amjad EH, Lonardo F (2006). Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu. Int J Cancer 119 : 441 454.
51. Pinkston JA, Cole P (1999). Incidence rates of salivary gland tumours: results from a population based study. Otolaryngol Head Neck Surg 6 : 834 840.
52. Ponz-Sarvise M, Rodriguez J, Viudez A et al (2007). Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new? World J Gastroenterol 13 : 5877 5887.
53. Pramoonjago P, Baras AS, Moskaluk CA (2006). Knockdown of Sox4 expression by RNAi induces apoptosis in ACC3 cells. Oncogene 25 : 5626 5639.
54. Queimado L, Lopes CS, Reis AM (2007). WIF1, an inhibitor of the Wnt pathway, is rearranged in salivary gland tumours. Genes Chromosomes Cancer 46 : 215 225.
55. Queimado L, Obeso D, Hatfield MD, Yang Y, Thompson DM, Reis AM (2008). Dysregulation of Wnt pathway components in human salivary gland tumours. Arch Otolaryngol Head Neck Surg 134 : 94 101.
56. Ries LAG, Hankey BF, Miller BA et al (1991). Cancer statistics review 1973-88. National Cancer Institute : Bethesda, MD. NIH Publication No. 91-2789.
57. Rodenhuis S (1992). Ras and human tumours. Semin Cancer Biol 3 : 241 247.
58. Rugo HS, Herbst RS, Liu G et al (2005). Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumours: pharmacokinetic and clinical results. J Clin Oncol 23 : 5474 5483.
59. Sato N, Kyakumoto S, Sawano K, Oto M (1996). Proliferative signal transduction by epidermal growth factor (EGF) in the human salivary gland adenocarcinoma (HSG) cell line. Biochem Mol Bio Int 38 : 597 606.
60. Schoenmakers EFPM, Wanschura S, Mols R et al (1995). Recurrent rearrangements in the hight mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nat Genet 10 : 436 444.
61. Schweighoffer F, Faure M, Fath I et al (1993). Identification of a human guanine nucleotide-releasing factor (H-GRF55) specific for Ras proteins. Oncogene 8 : 1477 1485.
62. Skalova A, Starek Kucerova V, Szepe P, Plank L (2001). Salivary duct carcinoma - a highly aggressive salivary gland tumour with HER2/neu oncoprotein overexpression. Pathol Res Pract 197 : 621 626.
63. Spiro RH (1986). Salivary neoplasms: overview of 35-year experience with 2807 patients. Head Neck Surg 8 : 177 184.
64. Stenman G, Sandros J, Mark J, Nordkvist A (1989). High p21RAS expression levels correlate with chromosome 8 rearrangements in benign human mixed salivary gland tumours. Genes Chromosomes Cancer 1 : 59 66.
65. Subhashraj K (2008). Salivary gland tumours: a single institution experience in India. Br J Oral Maxillofac Surg 46 : 235 238.
66. Tonon G, Modi S, Wu L et al (2003). t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signalling pathway. Nat Genet 33 : 208 213.
67. Van Dyck F, Declercq J, Braem CV, Van de Ven WJ (2007). PLAG1, the prototype of the PLAG gene family: versatility in tumour development (review). Int J Oncol 30 : 765 774.
68. Van Halteren HK, Top B, Mooi WJ, Balm AJ, Rodenhuis S (1994). Association of H-ras mutations with adenocarcinomas of the parotid gland. Int J Cancer 57 : 362 364.
69. Voz ML, Mathys J, Hensen K et al (2004). Microarray screening for target genes of the proto-oncogene PLAG1. Oncogene 23 : 179 191.
70. Wang J, Dong F, Wang X (1997). Quantitative studies of oncogene ras P21 and P53 gene protein expression in the benign and malignant pleomorphic adenomas of salivary gland. Zhongua Kou Qiang Yi Xue Za Zhi (original article in Chinese - translation of abstract available online) 32 : 208 211.
71. Williams DE, Eisenmann J, Baird A et al (1990). Identification of ligand for the c-kit proto-oncogene. Cell 63 : 167 174.
72. Wu JX, Carpenter PM, Gressens C et al (1990). The proto-oncogene c-fos is overexpressed in the majority of human osteosarcomas. Oncogene 5 : 989 1000.
73. Yoo J, Robinson RA (2000a). Ras gene mutations in salivary gland tumours. Arch Pathol Lab Med 124 : 836 839.
74. Yoo J, Robinson RA (2000b). H-ras gene mutations in salivary gland mucoepidermoid carcinomas. Cancer 88 : 518 523.
75. Zachos G, Spandidos DA (1997). Expression of ras proto-oncogenes: regulation and implications in the development of human tumours. Crit Rev Oncol Haematol 26 : 65 75.
76. Zakut R, Perlis R, Eliyahu S et al (1993). KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells. Oncogene 8 : 2221 2229.
77. Zhao X, Ren W, Yang W et al (2006). Wnt pathway is involved in pleomorphic adenomas induced by overexpression of PLAG1 in transgenic mice. Int J Cancer 118 : 643 648.
78. Zsebo K, Williams DA, Geissler EN et al (1990). Stem cell factor is encoded at the S1 locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 63 : 213 224.